In Vivo Models of Inflammation

Volume 1
2. Auflage 2006
ISBN: 978-3-7643-7520-1
Verlag: Springer
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, 211 Seiten

In Vivo Models of Inflammation (Vol. 1) provides biomedical researchers in both the pharmaceutical industry and academia with a description of the state-of-the-art animal model systems used to emulate diseases with components of inflammation. This second edition acts as a complement to the first, describing and updating the standard models that are most utilized for specific disease areas. New models are included exploring emerging areas of inflammation research.

Autoren/Hrsg.

Inhaltsverzeichnis

1;Contents;5
2;List of contributors;7
3;Preface to the first edition;10
4;Preface to the second edition;11
4.1;Introduction;12
4.2;Historical background;12
5;Rat models of arthritis: Similarities, differences, advantages, and disadvantages in the identification of novel therapeutics;12
5.1;Drug therapies;13
5.2;Methods;27
5.3;Conclusions;33
5.4;References;36
5.5;Introduction;46
6;Murine collagen induced arthritis;46
6.1;Induction of CIA;47
6.2;Expression of arthritis;50
6.3;Unilateral CIA;52
6.4;CIA in C57BL/6 mice;53
6.5;Passive transfer model of CIA;53
6.6;Arthritis score and histopathology;54
6.7;Cytokine involvement;58
6.8;Applicability of the model;65
6.9;Final remarks;69
6.10;References;70
6.11;Introduction;75
7;Use of animal models of osteoarthritis in the evaluation of potential new therapeutic agents;75
7.1;OA animal models;76
7.2;Use of OA animal models in the evaluation of potential therapeutic modalities;76
7.3;Conclusion;78
7.4;References;86
7.5;Introduction: Inflammation and cancer;93
8;Models of inflammatory processes in cancer;93
8.1;Inflammation as an initiator;94
8.2;Inflammation as a promoter;94
8.3;Inflammation as an immunosuppressor;94
8.4;Models of the initiator/promotor activities of inflammation;95
8.5;Models of angiogenesis;96
8.6;In vivo tumor models;100
8.7;Inflammation-related immune regulatory mechanisms;102
8.8;Conclusions;104
8.9;References;105
8.10;Introduction;113
8.11;Muscular dystrophy and the pathogenetic role of inflammation;113
9;Advances in stem cell research: use of stem cells in animal models of muscular dystrophy;113
9.1;Animal models of muscular dystrophy;116
9.2;Inflammation in the dystrophic models;117
9.3;Muscular dystrophy, regeneration and stem cells;119
9.4;Enhancing stem cell–mediated muscle regeneration;126
9.5;Future prospects;126
9.6;References;127
9.7;Introduction;134
10;Gene transfer technology;134
10.1;Principles of gene transfer;135
10.2;Non-viral methods for gene transfer;137
10.3;Viral vectors for gene transfer;137
10.4;Conclusion;143
10.5;References;144
10.6;Introduction;147
11;Transgenics;147
11.1;Background/literature summary;148
11.2;Experimental descriptions;154
11.3;Invasive and noninvasive methods to study inflammatory diseases;156
11.4;Conclusions;158
11.5;References;158
11.6;Introduction;163
12;Nanotechnology: Towards the detection and treatment of inflammatory diseases;163
12.1;Nanotechnology for inflammation scientists;164
12.2;Nanostructures and nanosystems;165
12.3;Nanoparticles;169
12.4;In vitro diagnostics;172
12.5;Nanoarrays;173
12.6;Application of nanosystems and nanoparticles in inflammation and cancer;173
12.7;Summary and conclusions;178
12.8;References;179
12.9;Introduction;185
13;UK legislation of in vivo aspects in inflammation research;185
13.1;UK legislation;186
13.2;The Certificate of Designation;188
13.3;The Project Licence;188
13.4;The Personal Licence;190
13.5;Other legislative systems in the United States and Europe;191
13.6;Opportunities for reduction, replacement and refinement in inflammation research;191
13.7;Skills shortages in integrative inflammation research in the 21st century;192
13.8;References;193
13.9;Legal standing of the 3R principle;195
14;Japanese guidelines and regulations for scientific and ethical animal experimentation;195
14.1;Basic guidelines established by regulatory agencies;196
14.2;Detailed guidelines formulated by the SCJ;197
14.3;Deliberation on local self-regulation of animal experiments;198
14.4;References;199
14.5;Introduction;200
15;United States guidelines and regulations in animal experimentation;200
15.1;Federal laws;201
15.2;Guide for the Care and Use of Laboratory Animals;204
15.3;Food and Drug Administration, Good Laboratory Practices;205
15.4;Specific considerations for animal models of inflammation;206
15.5;Summary;208
15.6;References;209
16;Index;210